Evolus (NASDAQ:EOLS) Trading Down 2.4% – Should You Sell?

Shares of Evolus, Inc. (NASDAQ:EOLS) fell 2.4% during mid-day trading on Monday . The company traded as low as $12.80 and last traded at $12.72. 41,269 shares were traded during trading, a decline of 93% from the average session volume of 590,097 shares. The stock had previously closed at $13.03.

Wall Street Analyst Weigh In

EOLS has been the subject of several research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Wednesday, March 5th. Barclays boosted their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Finally, HC Wainwright restated a “buy” rating and issued a $27.00 target price on shares of Evolus in a research note on Wednesday, March 5th.

Evolus Trading Down 2.3 %

The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The company has a market capitalization of $809.46 million, a P/E ratio of -13.99 and a beta of 1.28. The company’s fifty day simple moving average is $13.42 and its 200-day simple moving average is $13.87.

Insider Activity

In other news, Director Karah Herdman Parschauer sold 12,888 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total value of $167,415.12. Following the completion of the sale, the director now owns 32,183 shares of the company’s stock, valued at $418,057.17. This trade represents a 28.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $60,147.36. Following the transaction, the chief marketing officer now directly owns 95,671 shares in the company, valued at $1,268,597.46. This represents a 4.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,324 shares of company stock worth $716,856. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Evolus

Institutional investors have recently bought and sold shares of the stock. Jefferies Financial Group Inc. purchased a new position in shares of Evolus in the fourth quarter worth $753,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Evolus by 6.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,052 shares of the company’s stock worth $1,270,000 after acquiring an additional 6,821 shares during the last quarter. Zimmer Partners LP lifted its position in Evolus by 66.6% during the 4th quarter. Zimmer Partners LP now owns 416,500 shares of the company’s stock worth $4,598,000 after acquiring an additional 166,500 shares during the period. Tang Capital Management LLC grew its stake in Evolus by 3.1% during the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock valued at $55,171,000 after purchasing an additional 150,000 shares during the last quarter. Finally, Rafferty Asset Management LLC acquired a new position in shares of Evolus in the fourth quarter valued at about $115,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.